NetworkNewsBreaks – Oncotelic Therapeutics, Inc.
Post# of 64
(Total Views: 42)
Posted On: 10/08/2025 4:14:25 PM
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia
Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., announced that Sapu Nano presented its poster, “Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). The study marks the first clinical trial of an intravenous Deciparticle(TM) formulation of everolimus, an mTOR inhibitor used in breast cancer and other malignancies. Conducted in collaboration with SOCRU, Ingenū, and Medicilon, the trial (ACTRN12625001083482) is now enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia. “Sapu-003 represents a significant advance in the delivery of mTOR-targeted therapies,” said Dr. Vuong Trieu, CEO of Sapu Nano and Oncotelic. “Through these partnerships, we aim to accelerate development and bring this next-generation treatment to patients with advanced cancers.”
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., announced that Sapu Nano presented its poster, “Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). The study marks the first clinical trial of an intravenous Deciparticle(TM) formulation of everolimus, an mTOR inhibitor used in breast cancer and other malignancies. Conducted in collaboration with SOCRU, Ingenū, and Medicilon, the trial (ACTRN12625001083482) is now enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia. “Sapu-003 represents a significant advance in the delivery of mTOR-targeted therapies,” said Dr. Vuong Trieu, CEO of Sapu Nano and Oncotelic. “Through these partnerships, we aim to accelerate development and bring this next-generation treatment to patients with advanced cancers.”
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)